1 / 18

Stop TB Partnership

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary. Stop TB Partnership. What: A global social movement to Stop TB Need for multisectoral approach New opportunities to work in partnership Vision: A TB-free world Mission:

raja-mckay
Download Presentation

Stop TB Partnership

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHO Expert Working Group on R&D FinancingStop TB New Tools Working GroupsMarcos EspinalExecutive Secretary

  2. Stop TB Partnership • What: A global social movement to Stop TB • Need for multisectoral approach • New opportunities to work in partnership • Vision: A TB-free world • Mission: • Ensure that every TB patient has access to effective diagnosis, treatment and cure • Stop transmission of TB • Reduce the inequitable social and economic toll of TB • Develop and implement new preventive, diagnostic and therapeutic tools and strategies to stop TB

  3. Targets for global TB controlMILLENNIUM DEVELOPMENT GOALS"to have halted and begun to reverse incidence.." Implementation (DOTS)Target year Case detection 70% 2005 Treatment success 85% 2004/5 Impact Prevalence 50% of ≈ 300/100K 2015 Deaths 50% of ≈ 30/100K (<1m) 2015 Incidence <1 per million 2050

  4. Principles and Values of Stop TB • Urgency • Equity • Shared responsibility • Inclusiveness • Consensus • Sustainability • Dynamism

  5. Governance and Structure Global Partners Forum WHO Technical Advisory Group Coordinating Board Partnership Secretariat Global TB Drug Facility W O R K I N G G R O U P S New TB Diagnostics New TB Vaccines New TB Drugs DOTS expansion TB/HIV MDR-TB Advocacy Network

  6. Partnership towards Stop TB Targets Partners Forum TB/HIV WG DOTS Expansion WG Coordinating Board Secretariat/GDF TB Diagnostics WG DOTS-Plus MDRTB WG Goals & Targets New Vaccines WG New Drugs WG Communication/ Advocacy WG

  7. The Global Plan to Stop TB

  8. The Global Plan 10-year perspective on the road to 2050 Response to country needs for long-term planning Outlines financial requirements for sustainability A pathway towards the Partnership's targets for 2015 and goal for 2050 A Plan with credibility will serve a key advocacy role Treatment of 50 million people with TB, 3 million TB/HIV co-infected patients on ARV, and ~ 1 million with MDR Saving of 14 million lives from 2006-2015 The first new TB drug introduced by 2010 The "point of care" diagnostics introduced by 2010 Develop a new vaccine by 2015

  9. Research & Development WGs

  10. Funding gap: $ 31 bn

  11. Total costs for implementation and new tools, 2006-2015

  12. Global Plan: The Next Decade of TB R&D Diagnostics $0.52B Drugs $4.8B Vaccines $3.6 B

  13. BMGF has committed more than 900 million US$ to the Global Plan needs on R&D

  14. Mission & Objectives of Stop TB Vaccine WG I. Mission • To ensure the availability of a safe, effective and reasonably priced new TB vaccine by 2015 II. Objectives • Coordinate international activities that strengthen and accelerate the development and introduction of improved TB vaccines • Promote a concerted approach to development and introduction of improved TB vaccines by encouraging interactions among groups involved in scientific research, clinical/epidemiological investigations, industrial development, regulatory and public health programs • Develop and implement a strategic action plan for the Initiative for Vaccine Research program at WHO to provide a framework for the development, clinical study and introduction of improved TB vaccines • Interact with Partners to identify significant impediments to commercial development of improved TB vaccines and establish mechanisms for cooperation and collaborations that lead to accelerated vaccine development 2003 2004

  15. Governance and working environment • Chair: Michel Greco, Parterurop, France • Secretariat: Uli Fruth, Initiative for Vaccine Research, WHO • Core Group: Various Stakeholders • Sub-groups: • Innovative approaches to new TB vaccines • Harmonization of laboratory assays for TB vaccine development • Clinical research issues • Advocacy for TB vaccine • Economics and product profiles • WG meets once a year, sets its own agenda and workplan • Partners in the WG maintain their own independence and plans • Funded in part by the Stop TB Partnership Secretariat (50% of its operational budget) and partners • Liaison Officer in the Partnership Secretariat 2003 2004

  16. promote global access promote global access Role of the Working Group on New Vaccines preclinical clinical trials manufacture Gates (Aeras) EU (TB-VAC, EDCTP) NIH, Wellcome . .

  17. Developing new TB vaccines

  18. Recommendation 7: The Partnership should continue to use Working Groups as a major vehicle contributing to TB control and research, systematize the processes for their establishment and performance review, and provide them support from the Secretariat Independent Evaluation of the Stop TB Partnership. Final Report. 21 April 2008. Mckinsey & Company. 2003 2004

More Related